Alzheimer's

Alzheimer's

Alzheimer's

Having a father with Alzheimer's can increase the risk of suffering from it more than having an affected mother

While some studies have suggested that having a mother with Alzheimer's may increase the risk of developing the disease, a new study reveals that having a father with the disease may be related to a greater spread of tau protein in the brain, which is a sign of the disease. The study, published in Neurology, does not prove that having a father with Alzheimer's causes these brain changes; it only shows an association.

0

A blood marker for detecting Alzheimer's disease tested

An international team with Spanish participation has analysed the usefulness of a blood biomarker - the p-tau217 protein - for detecting Alzheimer's disease in 1,767 patients. According to the authors, who publish the results in the journal Nature Medicine, the test has detected the disease with high reliability in four hospital cohorts, as well as in a primary care cohort. They add that it is an assay that can be easily implemented in clinical laboratories and is already routinely used in some centres in Spain.

0

EMA recommends not approving donanemab for Alzheimer's

EMA’s human medicines committee has recommended not authorising the marketing of Kisunla (donanemab), a drug intended for the treatment of early-stage Alzheimer's disease. The committee considered that the benefits of this drug were not great enough to outweigh the risk of potentially fatal events. In recent years, several patients have died due to microbleeds in the brain.

0

Early administration of an anti-amyloid therapy could delay the onset of Alzheimer's disease

The DIAN-TU platform is an initiative to test Alzheimer's disease treatments early, by recruiting people with a mutation that leads to developing the disease in the future. One of the trials with the anti-amyloid drug gantenerumab ended without reaching the targets. However, a continuation of the study in 73 patients suggests - for the first time, according to the authors - that long-term, high-dose treatment given some time before symptoms develop could delay the onset of the disease. The results are published in the journal The Lancet Neurology. 

0

Association found between the use of drugs such as vaccines, antibiotics or anti-inflammatory drugs and lower risk of dementia

A review of 14 studies and data from more than 130 million patients has found an association between the use of drugs such as anti-inflammatory drugs, antibiotics and vaccines and a reduced risk of dementia. The authors recall that “the fact that a particular drug is associated with an altered risk of dementia does not necessarily mean that it causes or helps against it.” However, “pooling these huge health data sets provides a source of evidence that can help us decide which drugs to try first.” The research is published in the journal Alzheimer's and Dementia: Translational Research & Clinical Interventions. 

0

New nasal treatment for Alzheimer's disease tested in mice

A study by Italian researchers has tested a treatment administered as a nasal spray to slow down early-stage Alzheimer's disease. Administered in mice, the treatment inhibits an enzyme linked to the disease and to insulin resistance. According to the researchers, who publish the work in the journal PNAS, application of the spray to the animals “can counteract the accumulation of harmful proteins in neurons and delay the onset and progression of cognitive decline”. 

0

EMA revises earlier decision and decides to approve lecanemab for Alzheimer's disease

Less than four months after the European Medicines Agency recommended in July not to grant marketing authorisation for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease, the EMA's Committee for Medicinal Products for Human Use (CHMP) has reassessed the available evidence to conclude that the benefits outweigh the risks.

 

0

How gender roles influence Alzheimer’s disease and why it must be investigated

Men and women could develop Alzheimer’s disease through different mechanisms. Understanding these differences is essential to design specific interventions and to treat the disease effectively. In an article published in Alzheimer’s and Dementia: The Journal of the Alzheimer’s Association, a group of researchers, including myself, have highlighted the urgency of adding a sex and gender approach to the studies on this pathology.

1

EMA recommends not to approve lecanemab against Alzheimer's disease

The European Medicines Agency (EMA) has recommended not granting marketing authorization for Leqembi™ (lecanemab) for the treatment of Alzheimer's disease. The EMA's Committee for Medicinal Products for Human Use (CHMP) considers that its effect in delaying cognitive decline does not outweigh the risk of serious side effects associated with the drug, in particular swelling and possible bleeding in patients' brains. Leqembi™ was approved in 2023 in the United States.

0